MolecuLight Announces ITC Has Instituted Investigation Following Prior Complaint
The respondents named in the investigation are Kent Imaging Inc. of
"We are pleased that the ITC has voted to institute this investigation," said
About MolecuLight
MolecuLight is a privately held medical imaging company with a global footprint, dedicated to manufacturing and commercializing the MolecuLight i:X® and DX® wound imaging devices. Both FDA-cleared Class II point-of-care systems provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The MolecuLightDX® additionally offers thermal imaging for comprehensive wound assessment. The technologies' effectiveness and clinical utility are supported by more than 100 peer-reviewed publications.
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculight-announces-itc-has-instituted-investigation-following-prior-complaint-302680117.html
SOURCE MolecuLight Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and
- Every enduring field of medicine is built on clinical architecture.
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share